Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva
{"title":"肉毒杆菌毒素治疗特发性膀胱过度活动症:实际效果和患者的期望。","authors":"Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva","doi":"10.1097/j.pbj.0000000000000164","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).</p><p><strong>Methods: </strong>Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.</p><p><strong>Results: </strong>A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (<i>P</i> <i>=</i> .01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (<i>P</i> = .73) nor it was related to age (<i>P</i> = .6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (<i>P</i> = .06).Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65 years old had less risk of developing a urinary tract infection (<i>P</i> = .04).</p><p><strong>Conclusion: </strong>In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"9 1","pages":"e164"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830074/pdf/","citationCount":"0","resultStr":"{\"title\":\"Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients' expectations.\",\"authors\":\"Pedro Abreu-Mendes, Inês Portugal-Rodrigues, Luis Vale, Paulo Dinis, Francisco Cruz, Tiago Antunes-Lopes, Carlos Martins-Silva\",\"doi\":\"10.1097/j.pbj.0000000000000164\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).</p><p><strong>Methods: </strong>Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.</p><p><strong>Results: </strong>A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (<i>P</i> <i>=</i> .01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (<i>P</i> = .73) nor it was related to age (<i>P</i> = .6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (<i>P</i> = .06).Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65 years old had less risk of developing a urinary tract infection (<i>P</i> = .04).</p><p><strong>Conclusion: </strong>In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.</p>\",\"PeriodicalId\":41844,\"journal\":{\"name\":\"Nephrologe\",\"volume\":\"9 1\",\"pages\":\"e164\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830074/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nephrologe\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/j.pbj.0000000000000164\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/j.pbj.0000000000000164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients' expectations.
Background: Overactive bladder (OAB) is a prevalent syndrome affecting 11% to 16% of the adult population. When first-line pharmacological therapy is not effective, intradetrusorial injections of onabotulinumtoxinA (BTX-A) might have an important role in controlling symptoms. The main aim of this study was to access both the efficacy and safety of intradetrusor injections of 100U BTX-A in real clinical practice, among women with idiopathic OAB (iOAB).
Methods: Retrospective study, based on clinical diaries in 136 iOAB female patients, with or without urinary incontinence, submitted to BTX-A injections, between 2005 and 2018 in a tertiary university hospital. Positive response was considered only when the patient mentioned she had great improvement after the injection, otherwise, it was considered negative.
Results: A positive response was obtained in 90 patients (66%) after the first injection. Women with a positive response after the first treatment had 7.5 times more chances to improve with the second (P= .01). Discontinuation of the therapy after the first injection was neither dependent on the presence of incontinence at baseline (P = .73) nor it was related to age (P = .6). On univariate analyses, none of the parameters evaluated was useful of predicting successful response, although there was a trend in women who had had a previous midurethral sling surgery for stress urinary incontinence, to have a lower chance of having a positive response after the first injection (P = .06).Thirty-nine women (29%) had at least 1 adverse event, urinary tract infection, and straining to void were the most frequent. Women above 65 years old had less risk of developing a urinary tract infection (P = .04).
Conclusion: In real clinical practice, BTX-A injection is an effective (66%) and safe treatment, capable of improving quality of life. Moreover, responding to the first injection seems to predict good clinical outcomes in the second treatment. This procedure can be done with minimal restrictions.
期刊介绍:
Zielsetzung der Zeitschrift
Der Nephrologe bietet aktuelle und kompakte Fortbildung für alle nephrologisch tätigen Ärzt*innen in Klinik und Praxis. Inhaltlich werden sämtliche Bereiche der angewandten Nephrologie und Hypertensiologie praxisnah abgedeckt. Das Spektrum reicht von der Prävention, diagnostischen Vorgehensweisen und Komplikationsmanagement bis hin zu modernen Therapiestrategien.
Umfassende Übersichtsarbeiten zu einem aktuellen Schwerpunktthema sind das Kernstück jeder Ausgabe. Im Mittelpunkt steht dabei gesichertes Wissen zu Diagnostik und Therapie mit hoher Relevanz für die tägliche Arbeit.
Beiträge der Rubrik "CME Zertifizierte Fortbildung" bieten gesicherte Ergebnisse wissenschaftlicher Forschung und machen ärztliche Erfahrung für die tägliche Praxis nutzbar. Nach Lektüre der Beiträge können die Leser*innen ihr erworbenes Wissen überprüfen und online CME-Punkte erwerben. Die Rubrik orientiert sich an der Weiterbildungsordnung des Fachgebiets.
Aims & Scope
Der Nephrologe offers up-to-date information for all nephrologists working in practical and clinical environments and scientists who are particularly interested in issues of nephrology.
The content covers all areas of applied nephrology and hypertensiology. The topics range from prevention to diagnostic approaches and management of complications to current therapy strategies.
Comprehensive reviews on a specific topical issue provide evidenced based information on diagnostics and therapy.
Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.
Review
All articles of Der Nephrologe are reviewed.
Declaration of Helsinki
All manuscripts submitted for publication presenting results from studies on probands or patients must comply with the Declaration of Helsinki.